Last reviewed · How we verify
NCT04812106
Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
trial testing No Intervention in Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) in 8 participants. Terminated before completion.
27 October 2022
Quick facts
| Lead sponsor | Ultragenyx Pharmaceutical Inc |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 25 July 2022 |
| Primary completion | 27 October 2022 |
| Estimated completion | 27 October 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- No Intervention
Conditions studied
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) — all drugs for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) →
Sponsor
Ultragenyx Pharmaceutical Inc — full company profile →
Who can join
Eligibility, any sex, with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD community, by use of a convenient online platform for participants (or caregivers) to self-report information.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04812106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Intervention
Trials testing the same drug.
- NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
- NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
- NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
- NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
- NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting
Other Ultragenyx Pharmaceutical Inc trials
Trials by the same sponsor.
- NCT05196165 — Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storag · terminated
- NCT05312697 — Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta · Phase 2 · terminated
- NCT04783428 — Tumor-induced Osteomalacia Disease Monitoring Program · active not recruiting
- NCT05139316 — A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen S · Phase 3 · completed
- NCT04990388 — Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04812106 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ultragenyx Pharmaceutical Inc
- Last refreshed: 18 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04812106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing